Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant palbociclib plus hormonal therapy vs hormonal therapy plus placebo in operable HR-positive, HER2-negative breast cancer
jRCT2091220424Phase 3Completed
- Sponsor
- Kyoto Breast Cancer Research Network
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Palbociclib plus hormonal therapy with Placebo plus hormonal therapy (2 arms). Primary endpoints: PEPI score and EndoPredict EPclin score. Started May 2019; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2091220424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220424.